Analyst Ratings For NASDAQ:FPRX – Five Prime Therapeutics (NASDAQ:FPRX)
Today, JPMorgan Chase & Co. initiated coverage on NASDAQ:FPRX – Five Prime Therapeutics (NASDAQ:FPRX) with a Neutral with a price target of $19.00.
Some recent analyst ratings include
- 6/15/2018-JPMorgan Chase & Co. initiated coverage with a Neutral rating.
- 5/17/2018-Wedbush initiated coverage with a Neutral rating.
- 5/10/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
- 9/12/2017-Jefferies Financial Group Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:FPRX – Five Prime Therapeutics (NASDAQ:FPRX)
NASDAQ:FPRX – Five Prime Therapeutics (NASDAQ:FPRX) has insider ownership of 6.40% and institutional ownership of 91.04%.
- On 11/1/2017 William R Ringo, Director, sold 600 with an average share price of $45.33 per share and the total transaction amounting to $27,198.00.
- On 10/2/2017 William R Ringo, Director, sold 1,800 with an average share price of $40.26 per share and the total transaction amounting to $72,468.00.
- On 9/28/2017 William R Ringo, Director, sold 2,000 with an average share price of $38.00 per share and the total transaction amounting to $76,000.00.
- On 3/1/2017 William R Ringo, Director, sold 500 with an average share price of $46.73 per share and the total transaction amounting to $23,365.00.
- On 2/1/2017 William R Ringo, Director, sold 500 with an average share price of $46.17 per share and the total transaction amounting to $23,085.00.
- On 1/18/2017 Francis Willard Sarena, Insider, sold 3,636 with an average share price of $47.39 per share and the total transaction amounting to $172,310.04.
- On 1/3/2017 William R Ringo, Director, sold 500 with an average share price of $51.07 per share and the total transaction amounting to $25,535.00.
Recent Trading Activity for NASDAQ:FPRX – Five Prime Therapeutics (NASDAQ:FPRX)
Shares of NASDAQ:FPRX – Five Prime Therapeutics closed the previous trading session at 17.13 down -0.51 2.89% with 17.1299991607666 shares trading hands.